Barely Significant
← all excerpts

Twice against thrice-weekly hemodialysis (TATH): a multicenter nonrandomized trial.

BMC Nephrol · 2025 · PMC11972488 · PMID 40188011

Europe PMCDOI
1
hedged sentence
0.0800
closest p · 1.6× alpha
0.0800
boldest claim

The sentences

showed a trendP = 0.08so close (0.05 < p ≤ 0.1)
The twice-weekly group showed a trend toward higher erythropoietin requirements ( P = 0.08).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.